Vivesto AB (VIVEs)
Market Closed
CBOE CBOE Primary 111.82M Market Cap
- P/E Ratio
- Div Yield
- Volume
0 Eps
Want to track VIVEs and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Summary
VIVEs is not paying dividends to its shareholders.
Vivesto AB has completed 1 stock splits, with the recent split occurring on May 20, 2026.
The company's stock is traded on one exchange.
Vivesto AB (VIVEs) FAQ
On which exchange is it traded?
Vivesto AB is listed on CBOE.
What is its stock symbol?
The ticker symbol is VIVEs.
Does it pay dividends? What is the current yield?
It does not pay dividends to its shareholders.
What is its market cap?
As of today, the market cap is 111.82M.
Has Vivesto AB ever had a stock split?
Vivesto AB had 1 splits and the recent split was on May 20, 2026.
Vivesto AB Profile
| Specialty Retail Industry | Consumer Discretionary Sector | Erik Kinnman Assoc. CEO | CBOE Exchange | - ISIN |
| SE Country | 4 Employees | - Last Dividend | 20 May 2026 Last Split | - IPO Date |
Overview
Vivesto AB, based in Solna, Sweden, operates within the pharmaceutical sector focusing on the development, production, marketing, and sale of drugs specifically in the niche of human and veterinary oncology. Originally incorporated in 1988 as Oasmia Pharmaceutical AB (publ), the company underwent a rebranding to Vivesto AB in March 2022. Over the years, Vivesto AB has positioned itself as a key player in the oncology pharmaceutical market in Sweden by advancing its product development to address critical needs in cancer treatment.
Products and Services
- Apealea (paclitaxel micellar): This is Vivesto AB’s flagship product intended for the treatment of ovarian cancer. Apealea employs a micellar formulation of paclitaxel aimed at enhancing the delivery and efficacy of the treatment for patients suffering from this type of cancer.
- Docetaxel Micellar: This patented formulation is a unique combination of the cytotoxin docetaxel with XR-17 technology. It is currently in Phase 1b clinical trials targeting the treatment of prostate cancer, showcasing the company's commitment to diversifying its oncology portfolio with a focus on innovation and targeted therapy.
- Cantrixil: Developed for the treatment of ovarian cancer, Cantrixil is part of Vivesto AB's efforts to broaden its oncology offerings. This product underscores the company's dedication to combating ovarian cancer through advanced therapeutic options.
- Paccal Vet: Catering to the veterinary oncology market, Paccal Vet utilizes the same XR-17 encapsulation technology seen in Vivesto’s human oncology products but is designed for the treatment of canine mastocytoma. This product highlights the company's venture into extending its expertise in cancer treatment to animal health.
- Doxophos Vet: Another veterinary oncology product, Doxophos Vet is a patented formulation of doxorubicin aimed at treating lymphoma in animals. By offering such innovative solutions, Vivesto AB signifies its contribution towards advancing veterinary oncology treatments alongside its human counterparts.
Contact Information
Address: Gustav III:s Boulevard 46
Phone: 46 18 50 54 40
Website: https://www.vivesto.com
